<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/10.17917/NZYM-3K29" scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method ITA-5.1: Qualitative Analysis of Total Complement Activation by Western Blot</p><p><b>Protocol Abbreviation:</b> ITA-5.1</p><p><b>Protocol Version:</b> 3.1<hr><p><b>DOI:</b> <a href = http://dx.doi.org/10.17917/NZYM-3K29>http://dx.doi.org/10.17917/NZYM-3K29</a></p><p><b>Protocol File:</b> NCL_Method_ITA-5.1.pdf<p><b>File Title:</b> ITA-5.1</p><p><b>Description:</b></b> This document describes a protocol for qualitative determination of total complement activation by Western blot analysis. Human plasma is exposed to a test material and subsequently analyzed by polyacrylamide gel electrophoresis (PAGE) and Western blot with anti-C3 specific antibodies. These antibodies recognize both the native C3 component of the complement and its cleaved products. When the test compound or positive control (cobra venom factor) induces activation of the complement system, the majority of the C3 component is cleaved and appearance of C3 cleavage products is documented.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>